Search Within

Adult Leukemia

  1. "Benjamin Durham"
Formats
  1. Journal Article (22)
  2. Meeting Abstract (22)
Groups
  1. Center for Hematologic Malignancies (44)
  2. Department of Medicine (44)
  3. Hematologic Malignancies, Division of (44)
  4. Executive Committee, Center for Hematologic Malignancies (41)
  5. GSK Faculty (41)
  6. Human Oncology and Pathogenesis Program (41)

More Groups

People
  1. Benjamin Durham (44)
  2. Omar Abdel-Wahab (34)
  3. Raajit Rampal (22)
  4. Eli Diamond (21)
  5. David Hyman (13)
  6. Young Rock Chung (13)

More People

Years
  1. 2023 (6)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (4)
  5. 2019 (4)
  6. 2018 (4)

More Years

Publications
  1. Blood (19)
  2. Pediatric Blood and Cancer (4)
  3. Nature Medicine (3)
  4. Neuro-Oncology (2)
  5. British Journal of Haematology (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. Nature Publishing Group (7)
  3. Wiley Periodicals, Inc (4)
  4. American Association for Cancer Research (2)
  5. Massachusetts Medical Society (2)
  6. Oxford University Press (2)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Clonal characterization and somatic hypermutation assessment by next-generation sequencing in chronic lymphocytic leukemia/small lymphocytic lymphoma: A detailed description of the technical performance, clinical utility, and platform comparison
    Journal Article

    Petrova-Drus, K.; Syed, M.; Yu, W.; Hutt, K.; Zlotnicki, A. M.; Huang, Y.; Kamalska-Cyganik, M.; Maciag, L.; Wang, M.; Ma, Y. G.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
    Journal Article

    Wang, E.; Mi, X.; Thompson, M. C.; Montoya, S.; Notti, R. Q.; Afaghani, J.; Durham, B. H.; Penson, A.; Witkowski, M. T.; Lu, S. X.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Therapeutic efficacy of combined JAK1/2, pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
    Journal Article

    Rampal, R. K.; Pinzon-Ortiz, M.; Hanasoge Somasundara, A. V.; Durham, B.; Koche, R.; Spitzer, B.; Mowla, S.; Krishnan, A.; Li, B.; An, W.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • ZRSR2 mutation induced minor intron retention drives MDS and diverse cancer predisposition via aberrant splicing of LZTR1
    Meeting Abstract

    Inoue, D.; Polaski, J. T.; Taylor, J.; Castel, P.; Chen, S.; Kobayashi, S.; Hogg, S. J.; Hayashi, Y.; Pineda, J. M. B.; Penson, A. V.; more...
    Blood (2020)

    Fulltext@MSK | Save